The Gliknik Board of Directors has deep industry expertise with a track record for discovering and developing marketed drugs and generating successful exits for investors.
David S. Block – Chairman and CEO
Dr. Block founded Gliknik in 2007 after 17 years in industry, 12 of which were in a series of commercial positions at DuPont Merck and DuPont Pharmaceuticals including sales management, licensing, R&D portfolio planning, market development, and product launch. He was the EVP of International Operations at the time of the sale of DuPont Pharmaceuticals to Bristol-Myers Squibb. From 2002 to 2004, Dr. Block was the Chief Operating Officer of Celera Genomics. Prior to founding Gliknik, he formed and ran a venture-backed CNS start-up. Dr. Block received a BA from Wesleyan University in biopsychology, an M.D. from the University of Pennsylvania School of Medicine where he was class co-president, and an MBA in Entrepreneurism in Health Care from the Wharton School where he was the Beta Gamma Sigma scholar of his class. He is board-certified in Internal Medicine. Dr. Block currently is a director of Cocrystal Pharma, Inc. and has served on several non-profit Boards. For more than 25 years he has provided ongoing medical care to HIV positive patients as a volunteer at Johns Hopkins.
Paul A. Friedman, M.D. – Non-executive Director
Dr. Friedman has served as a member of our Board of Directors since 2013. He is currently the Chairman and CEO of Madrigal Pharmaceuticals and was formerly the Chief Executive Officer of Incyte Corporation. Under Dr. Friedman’s leadership, Incyte developed and launched Jakafi® (ruxolitinib), an FDA-approved drug for patients with intermediate or high-risk myelofibrosis. From 1994 to 1998, Dr. Friedman served as President of R & D for the DuPont Merck Pharmaceutical Company and from 1998 to 2001 as the President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of the DuPont Company. From 1991 to 1994, he served as Senior Vice President at Merck Research Laboratories. In these positions, Dr. Friedman has overseen the discovery and development of numerous drugs and brought Sustiva® (efavirenz) to market. Prior to his work at Merck and DuPont, Dr. Friedman was an associate professor of medicine and pharmacology at Harvard Medical School. Dr. Friedman is a diplomate of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. He received his A.B. in biology from Princeton University and his M.D. from Harvard Medical School. Dr. Friedman is also a director of Navitor, Incyte and Cerulean.
Skip Klein – Non-executive Director
Mr. Klein has served as a member of our Board of Directors since 2008. Mr. Klein is currently Managing Director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. Mr. Klein is a Director of Ionis Pharmaceuticals, Inc., a public biopharmaceutical company, as well as of the Prospector Funds, Inc., an SEC-registered investment company that manages two no-load mutual funds. He has previously served on the boards and Audit Committees of BioMarin Pharmaceutical, Inc.; Clinical Data, Inc.; Genaissance Pharmaceuticals, Inc.; Guilford Pharmaceuticals, Inc.; NPS Pharmaceuticals, Inc.; OSI Pharmaceuticals, Inc.; PDL BioPharma, Inc.; Savient Pharmaceuticals, Inc.; and Synbiotics, Inc. Mr. Klein also serves on the boards of private and non-profit entities. From 1989 to 1998, Mr. Klein was a health care investment analyst at T. Rowe Price Associates, Inc., where he was the founding portfolio manager of the T. Rowe Price Health Sciences Fund, Inc. He has previously served as a Venture Partner of Red Abbey Venture Partners, L.P. and of MPM Capital. Mr. Klein received a B.A., summa cum laude, in Economics from Yale University, and an MBA from the Graduate School of Business at Stanford University.
Mark D. Lerner – Non-executive Director
Mr. Lerner has served as a member of our Board of Directors since 2014. He is a Partner in Chesapeake Partners, a firm that he co-founded in 1991 to achieve above-average returns through “event specific” investing with a value overlay. Chesapeake Partners converted from being a hedge fund into a family investment office in 2016. Mr. Lerner has extensive investment banking experience analyzing, acquiring and managing a wide variety of businesses. Previously, Mr. Lerner worked with Resource Holdings Capital Group, a firm that invested and managed a leveraged buyout fund. Prior to that, Mr. Lerner participated in the acquisition and management of businesses, worked in the mergers and acquisitions group at Merrill Lynch Capital Markets, and was a credit analyst at the J. Henry Schroder Bank and Trust Co. Mr. Lerner earned a B.A. from the College of the University of Pennsylvania and a B.S. in Economics from the Wharton School of the University of Pennsylvania. He is Co-Chair of the Board of Baltimore’s Promise, a citywide collaborative whose mission is to coordinate strategy, identify quality programs, support alignment activities, establish shared measures for meaningful results, build public will, and advance policy on behalf of Baltimore City’s youth. Mr. Lerner is also a Director on the Board of Teach for America: Baltimore, a member of The Undergraduate Executive Board of the Wharton School of the University of Pennsylvania, a Distinguished Advisor to the Association of Universities for Research in Astronomy and was appointed a member of the Mayor of Baltimore’s Pay for Success Work Group. He served as the Chairman of a capital campaign that raised in excess of $16 million for The Park School of Baltimore, and completed a three year term as President of its Board of Trustees. Mr. Lerner co-chaired the Johns Hopkins Children’s Center Advisory Board, spearheading a campaign that raised more than $100 million needed to build a new Children’s and Maternal Health Hospital.
Richard S. Levy, M.D. – Non-executive Director
Richard S. Levy, M.D. has served as a member of our Board of Directors since 2014. Since December 2016, Dr. Levy has served as a Senior Advisor of Baker Bros. Advisors LP., a registered investment adviser focused on long-term investments in life-sciences companies on behalf of major university endowments and foundations. From January 2009 to April 2016, Dr. Levy served as Executive Vice President and Chief Drug Development Officer of Incyte Corporation, where he previously served as Senior Vice President of Drug Development from August 2003 to January 2009. Prior to joining Incyte, Dr. Levy served as Vice President, Biologic Therapies, at Celgene Corporation, a biopharmaceutical company, from 2002 to 2003. From 1997 to 2002, Dr. Levy served in various executive positions with DuPont Pharmaceuticals Company, first as Vice President, Regulatory Affairs and Pharmacovigilance, and thereafter as Vice President, Medical and Commercial Strategy. Dr. Levy served at Sandoz, a predecessor company of Novartis, from 1991 to 1997 in positions of increasing responsibility in clinical research and regulatory affairs. Prior to joining the pharmaceutical industry, Dr. Levy served as an Assistant Professor of Medicine at the UCLA School of Medicine. Dr. Levy is Board Certified in Internal Medicine and Gastroenterology and received his A.B. in Biology from Brown University, his M.D. from the University of Pennsylvania School of Medicine, and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA. Dr. Levy is also a director of Madrigal Pharmaceuticals and Aquinox Pharmaceuticals.
Raymond F. Schinazi, Ph.D., D.Sc. (Hon.) – Non-executive Director
Dr. Schinazi is the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University and Director of the Scientific Working Group on Viral Eradication for the NIH-sponsored Emory University Center for AIDS Research (CFAR). Dr. Schinazi received his B.Sc. (1972) and Ph.D. (1976) in chemistry from the University of Bath, England. He has authored over 550 peer-reviewed papers and seven books and holds 100 issued U.S. patents and over 120 non-U.S. national stage patents and patent applications, which have resulted in 16 New Drug Applications (NDA). A world leader in nucleoside chemistry, Dr. Schinazi is best known for his pioneering work on HIV and HCV drugs d4T (stavudine), 3TC (lamivudine), FTC (emtricitabine/Emtriva), LdT (telbivudine), and most recently sofosbuvir (Sovaldi), which are now approved by the FDA. He is also a founder of five biotechnology companies including Cocrystal Pharma (COCP); Pharmasset Inc. (acquired by Gilead in 2012), Triangle Pharmaceuticals (acquired by Gilead in 2003), and Idenix Pharmaceuticals (51 percent acquired by Novartis in 2003). More than 90% of HIV-infected individuals in the U.S. on combination therapy take at least one of the drugs he invented with hundreds of thousands of others treated worldwide. His contributions related to HCV have already had a profound positive impact on the approximately 170 million people worldwide suffering from chronic infection. Dr. Schinazi served on the Presidential Commission on AIDS and is the recipient of numerous distinguished awards. He served for 35 years for the Department of Veteran Affairs as Senior Research Career Scientist. He currently serves as a Governing Trustee for the Foundation for AIDS Research (amfAR) and as a Board member for the International Centre for Missing and Exploited Children (ICMEC).